Lumos Competitors

Pink Sheets . USA . 
Stock . Lumos Diagnostics Holdings
LDXHF Stock  USD 0.19  0.01  5.56%   
Lumos Diagnostics competes with BioPorto A/S, Shield Therapeutics, Orexo AB, Starpharma Holdings, and VITA 34; as well as few others. The company classifies itself under Healthcare sector and is part of Diagnostics & Research industry. Analyzing Lumos Diagnostics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Lumos Diagnostics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Lumos Diagnostics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Lumos Diagnostics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.1914.77
Details
Intrinsic
Valuation
LowRealHigh
0.010.1414.72
Details
Naive
Forecast
LowNextHigh
00.1714.75
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.090.150.22
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Lumos Diagnostics. Your research has to be compared to or analyzed against Lumos Diagnostics' peers to derive any actionable benefits. When done correctly, Lumos Diagnostics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Lumos Diagnostics.

Lumos Diagnostics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lumos Diagnostics and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Lumos and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lumos Diagnostics does not affect the price movement of the other competitor.

High positive correlations

ORXOF
+ 0.88
PFGTF
VTIAF
+ 0.7
PFGTF
VTIAF
+ 0.64
ORXOF
PBIGF
+ 0.46
VTIAF
SPHRF
+ 0.44
ORXOF
SPHRF
+ 0.38
PFGTF
  

High negative correlations

TOKIF
- 1.0
THOXF
SNZZF
- 0.65
PFGTF
SNZZF
- 0.5
ORXOF
SNZZF
- 0.39
SPHRF
PBIGF
- 0.32
CORBF
SNZZF
- 0.3
CORBF

Risk-Adjusted Indicators

There is a big difference between Lumos Pink Sheet performing well and Lumos Diagnostics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lumos Diagnostics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PFGTF  0.02  0.00  0.00  0.04  0.00 
 0.00 
 0.00 
 0.00 
 0.71 
CORBF  19.12  5.31  0.19  0.64  14.39 
(68.07)
 46.67 
(25.00)
 433.33 
THOXF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SHIEF  2.28  0.60  0.00  0.86  0.00 
 0.00 
 0.00 
 0.00 
 61.79 
TOKIF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
ORXOF  0.56  0.28  0.00 (6.49) 0.00 
 0.00 
 0.00 
 0.00 
 13.73 
SPHRF  5.03  2.22  0.00 (4.09) 0.00 
 0.00 
 4.55 
 0.00 
 150.43 
VTIAF  0.82  0.18  0.00  0.22  0.00 
 0.00 
 0.00 
 0.00 
 36.13 
PBIGF  4.88  0.61  0.05  0.40  5.49 
(13.13)
 16.67 
(13.33)
 60.62 
SNZZF  1.23 (0.36) 0.00 (0.64) 0.00 
 0.00 
 0.00 
 0.00 
 22.41 
All Fundamental Data

Lumos Diagnostics Competitive Analysis

The better you understand Lumos Diagnostics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lumos Diagnostics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lumos Diagnostics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LDXHF PFGTF CORBF THOXF SHIEF TOKIF ORXOF SPHRF VTIAF PBIGF
 5.56 
 0.19 
Lumos
 0.00 
 0.1 
Pacific
 26.67 
 0.95 
Global
 6.45 
 0.29 
BioPorto
 44.28 
 0.13 
Shield
 0.00 
 0.0001 
Optima
 5.17 
 3.05 
Orexo
 0.00 
 0.25 
Starpharma
 0.00 
 6.38 
VITA
 0.00 
 0.23 
Paradigm
Market Volatility
(90 Days Market Risk)
Out of control
Unstable
Unknown risk
Very steady
Out of control
Very steady
Not too volatile
Out of control
Slightly risky
Out of control
Market Performance
(90 Days Performance)
Fair
Fair
Mild
Weakest
Mild
Weakest
Fair
Good
Mild
Mild
Odds of Financial Distress
(Probability Of Bankruptcy)
Strong
Low
Unknown
Small
Moderate
Hazard
Small
Low
Small
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Not Rated
Strong Hold
Strong Sell
Buy
Strong Sell
Current Ratio
1.05
18.43
4.03
2.6
0.06
2.05
5.93
0.79
6.02
Net Asset
36.94 M
115.28 M
81.25 M
44.41 M
7.22 M
1.27 B
66.17 M
177.95 M
50.69 M
Profit Margin
N/A
-1.3
-2.5
N/A
-0.19
-0.28
N/A
-0.18
N/A
EBITDA
(42.73 M)
(21.8 M)
(58.6 M)
(17.35 M)
(2.75 M)
(141.3 M)
(16.63 M)
985 K
(39.16 M)
Operating Margin
-2.31
-1.56
-2.82
-7.83
0.0929
N/A
-3.13
-0.15
-604.99
Current Valuation
6.33 M
184.47 M
106.91 M
18.31 M
1.59 M
76.98 M
123.62 M
146.63 M
217 M
Price To Book
0.53
3.73
12.43
0.75
0.0915
2.02
4.36
3.67
8.76
Current Asset
N/A
N/A
N/A
N/A
N/A
907 M
50 M
N/A
N/A
Retained Earnings
N/A
N/A
N/A
N/A
N/A
N/A
(154 M)
N/A
N/A
Beta
N/A
0.87
1.49
1.1
2.52
0.72
0.85
0.79
1.12
Number Of Employees
10
100
31
15
17
126
50
775
16
Shares Outstanding
222.02 M
810.18 M
334.68 M
585.67 M
50.65 M
34.35 M
408.92 M
15.83 M
282.24 M
Cash Flow From Operations
(18.04 M)
(17.55 M)
(64.58 M)
(16.74 M)
(304.4 K)
(229 M)
(13.16 M)
2.73 M
(32.21 M)
Total Debt
7.19 M
1.92 M
10.42 M
156 K
57.08 K
492.3 M
4 M
10.93 M
616.67 K
Return On Equity
-1.2
-0.22
-0.88
-0.57
-0.1
-0.65
-0.29
-0.37
-0.65
Z Score
-2.1
77.4
6.6
N/A
18.6
N/A
21.2
6.0
N/A
Return On Asset
-0.25
-0.15
-0.41
-0.34
0.009
-0.0965
-0.14
-0.0503
-0.44
Book Value Per Share
0.085
0.12
0.27
0.15
0.062
1.07
0.12
2.25
0.18
Current Liabilities
N/A
N/A
N/A
N/A
N/A
303 M
10 M
N/A
N/A
Total Asset
36.94 M
115.28 M
81.25 M
44.41 M
7.22 M
1.27 B
66.17 M
177.95 M
50.69 M
Debt To Equity
0.4
0.017
0.12
0.003
0.41
1.76
0.17
0.84
0.014
Shares Owned By Institutions
21.45
29.21
8.6
13.58
0.65
42.78
44.65
15.38
18.7
Market Capitalization
14.54 M
248.38 M
121.23 M
51.48 M
1.78 M
58.7 M
161.85 M
110.48 M
347.15 M
Price To Earning
N/A
N/A
N/A
N/A
N/A
58.66
46.82
51.47
N/A
Price To Sales
0.81
15.54
9.27
7.37
0.92
0.99
28.59
2.18
3287.04
Net Income
(45.72 M)
(19.79 M)
(57.11 M)
(19.34 M)
(3.96 M)
(223.5 M)
(16.15 M)
(3.67 M)
(39.25 M)
Earnings Per Share
-0.15
-0.016
-0.03
-0.11
-0.007
N/A
-0.031
0.07
-0.14
Shares Owned By Insiders
45.75
7.86
19.84
42.23
19.89
17.29
6.1
67.61
16.46
Revenue
11.63 M
11.45 M
24.25 M
1.52 M
4.61 M
565 M
4.68 M
28.42 M
79.22 K
Working Capital
N/A
N/A
N/A
N/A
N/A
604 M
40 M
N/A
N/A
Cash And Equivalents
7.98 M
105.41 M
86.72 M
2.4 M
113
45.61 M
49.92 M
25.4 M
39.72 M
Cash Per Share
0.04
0.13
0.32
0.01
N/A
1.32
0.12
1.61
0.17
Gross Profit
1.19 M
6.64 M
15.04 M
539 K
1.38 M
521.7 M
(9.29 M)
12.44 M
(64.53 K)
Day Typical Price
0.19
0.0993
0.95
0.3
0.13
1.0E-4
3.0
0.25
6.38
0.23
Accumulation Distribution
0.05
N/A
N/A
0.0645
N/A
N/A
0.0492
N/A
N/A
N/A
Market Facilitation Index
0.01
N/A
N/A
0.02
N/A
N/A
0.15
N/A
N/A
N/A
Daily Balance Of Power
1.0
0.0
9.2 T
(1.00)
9.2 T
0.0
1.0
0.0
0.0
0.0
Period Momentum Indicator
0.01
N/A
0.2
(0.02)
0.0399
N/A
0.15
N/A
N/A
N/A
Rate Of Daily Change
1.06
1.0
1.27
0.94
1.44
1.0
1.05
1.0
1.0
1.0
Day Median Price
0.2
0.0993
0.95
0.3
0.13
1.0E-4
2.97
0.25
6.38
0.23
Price Action Indicator
N/A
N/A
0.1
(0.02)
0.02
N/A
0.15
N/A
N/A
N/A
Coefficient Of Variation
845.3
812.4
896.84
N/A
1163.61
N/A
627.34
725.31
1270.7
1215.97
Mean Deviation
9.54
0.0212
19.12
N/A
2.28
N/A
0.5553
5.03
0.818
4.88
Jensen Alpha
2.0
(0.0007)
5.31
N/A
0.5984
N/A
0.2793
2.22
0.1829
0.6107
Total Risk Alpha
0.2593
(0.01)
0.6146
N/A
(0.12)
N/A
0.097
0.5937
(0.08)
(0.17)
Sortino Ratio
0.0963
N/A
0.1851
N/A
N/A
N/A
N/A
N/A
N/A
0.0531
Downside Variance
291.89
N/A
1012.37
N/A
N/A
N/A
N/A
N/A
N/A
160.49
Standard Deviation
14.58
0.0874
53.53
N/A
7.7
N/A
1.8
15.87
3.55
9.15
Kurtosis
2.1
66.0
46.73
N/A
23.0
N/A
50.65
48.61
54.29
7.25
Potential Upside
30.0
N/A
46.67
N/A
N/A
N/A
N/A
4.55
N/A
16.67
Treynor Ratio
(0.42)
0.0369
0.6442
N/A
0.8582
N/A
(6.49)
(4.09)
0.2194
0.395
Maximum Drawdown
85.35
0.7099
433.33
N/A
61.79
N/A
13.73
150.43
36.13
60.62
Variance
212.64
0.0076
2865.43
N/A
59.3
N/A
3.23
251.85
12.57
83.78
Market Risk Adjusted Performance
(0.41)
0.0469
0.6542
N/A
0.8682
N/A
(6.48)
(4.08)
0.2294
0.405
Risk Adjusted Performance
0.0928
0.0161
0.0883
N/A
0.0696
N/A
0.1182
0.1066
0.0634
0.0671
Skewness
0.7028
8.12
6.32
N/A
3.02
N/A
6.96
6.47
6.73
1.71
Semi Deviation
9.89
N/A
14.39
N/A
N/A
N/A
N/A
N/A
N/A
5.49
Information Ratio
0.1128
(0.80)
0.11
N/A
0.0755
N/A
0.1147
0.1328
0.0561
0.0735
Value At Risk
(22.22)
N/A
(25.00)
N/A
N/A
N/A
N/A
N/A
N/A
(13.33)
Expected Short fall
(17.79)
N/A
(68.07)
N/A
N/A
N/A
N/A
N/A
N/A
(13.13)
Downside Deviation
17.08
N/A
31.82
N/A
N/A
N/A
N/A
N/A
N/A
12.67
Semi Variance
97.74
N/A
207.09
N/A
N/A
N/A
N/A
N/A
N/A
30.1

Lumos Diagnostics Competition Performance Charts

Five steps to successful analysis of Lumos Diagnostics Competition

Lumos Diagnostics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lumos Diagnostics in relation to its competition. Lumos Diagnostics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Lumos Diagnostics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lumos Diagnostics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lumos Diagnostics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Lumos Diagnostics position

In addition to having Lumos Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Value Funds Thematic Idea Now

Large Value Funds
Large Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Lumos Pink Sheet

Lumos Diagnostics financial ratios help investors to determine whether Lumos Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lumos with respect to the benefits of owning Lumos Diagnostics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY